Skip to content

Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease

Implantation Feasibility Study of a Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease (Smart in Vivo 2)

Status
Terminated
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02402569
Acronym
SIV2
Enrollment
2
Registered
2015-03-30
Start date
2014-12-31
Completion date
2018-12-31
Last updated
2019-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

This study aims to demonstrate innocuity and feasibility of deep brain stimulation with a multi-electrodes set.

Detailed description

Bilateral stimulation in subthalamic nucleus with the multi-electrodes set will be compared with single electrode.

Interventions

DEVICE32 channels Deep Brain Stimulator

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* more or equal than 18 years old and less than 70 years * patient affiliated to social security or similarly regime * informed consent form signed * parkinson disease (UPDRS III20 score up than 30/108 except for severe tremors) * motor and non motor dysfunctions * pre-operative cerebral MRI without lesion * without chirurgical contraindications * without psychiatric disease

Exclusion criteria

* Pregnant women and lactating mothers * Ward of court or under guardianship * Adult unable to express their consent * Person deprived of freedom by judicial or administrative decision * Person hospitalized without their consent * Person under legal protection * Person with carcinological antecedent during precedent 5 years * Chirurgical or MRI contraindications

Design outcomes

Primary

MeasureTime frameDescription
Safety, as measured by Number of Participants with Adverse Events3 monthsNumber of Participants with Adverse Events

Secondary

MeasureTime frameDescription
Neurologic evaluation3 monthsChange in motor and non-motor symptoms assessment with neurologic scales

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026